🔎 Trials Near Me

Beranda › Mieloma Multipel › Connecticut › New Haven

Uji klinis Mieloma Multipel di New Haven, CT

14 studi untuk Mieloma Multipel mencari peserta di lokasi sekitar New Haven (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

Menerima pesertaFase 2
  • Yale University School Of Medicine, New Haven
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06500884

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Menerima pesertaFase 3
  • Yale Cancer Center, New Haven
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07258511

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Menerima pesertaFase 1
  • Yale University, New Haven
  • Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi jauhnya
  • Smilow Cancer Hospital-Derby Care Center, Derby · 8 mi jauhnya
  • dan 1 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06465316

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Menerima pesertaFase 1/2
  • Smilow Cancer Center At Yale-New Haven /ID# 272447, New Haven
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06953960

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

Menerima pesertaFase 3
  • Yale University, New Haven
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07555938

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Menerima pesertaFase 1/2
  • Yale New Haven Hospital-Smilow Cancer Center, New Haven
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06988488

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Menerima pesertaFase 3
  • Smilow Cancer Center/Yale-New Haven Hospital, New Haven
  • Yale University, New Haven
  • Smilow Cancer Hospital-Orange Care Center, Orange · 5 mi jauhnya
  • dan 3 lainnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT04566328

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Menerima pesertaFase 3
  • Research Site, New Haven
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT07764978

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Menerima pesertaFase 3
  • Smilow Cancer Center/Yale-New Haven Hospital, New Haven
  • Yale University, New Haven
  • Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi jauhnya
  • dan 2 lainnya
Semua usia · Semua jenis kelamin · Diperbarui 10 Jun 2026 · NCT05561387

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Menerima pesertaFase 2
  • Yale University, New Haven
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Mei 2026 · NCT06993675

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Menerima pesertaFase 1
  • Yale Cancer Center, New Haven
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mar 2026 · NCT06153251

Uji klinis Mieloma Multipel di kota lain

Studi lain di New Haven

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.